scholarly journals Upregulation of Vascular Endothelial Growth Factor Receptor-3 in the Spinal Cord of Lewis Rats with Experimental Autoimmune Encephalomyelitis

2012 ◽  
Vol 61 (1) ◽  
pp. 31-44 ◽  
Author(s):  
Jang-Mi Park ◽  
Yoo-Jin Shin ◽  
Jeong Min Cho ◽  
Jae-Youn Choi ◽  
Sin-Soo Jeun ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Experimental Autoimmune Encephalomyelitis ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Autoimmune Encephalomyelitis ◽  
Lewis Rats ◽  
Endothelial Growth Factor ◽  
Experimental Autoimmune

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document